Determination of bortezomib and dasatinib anticancer drugs in real samples using an electrochemical sensor modified with new CuFe2O4/SmVO4/ionic liquid nanocomposite

Bortezomib (BTZ) and dasatinib (DA) are two substantial anti-cancer agents with side effects on the human body. In this research, we fabricated a novel electrochemical sensor modified by CuFe₂O₄/SmVO₄ nanocomposite and 1-ethyl-3-methylimidazolium chloride (1E3MC) as an ionic liquid (IL) (CuFe₂O₄/SmVO₄/IL/CPE) for coinciding investigation of BTZ and DA for the first time. The CuFe₂O₄/SmVO₄ synthesized were determined and certified through field-emission scanning electron microscopy (FE-SEM), energy diffraction X-ray (EDX), and X-ray diffraction (XRD). The capability of the sensor was investigated by different electrochemical techniques such as cyclic voltammetry (CV), chronoamperometry (CHA), differential pulse voltammetry (DPV), and electrochemical impedance spectroscopy (EIS). The attained data showed that the oxidation signal of bortezomib and dasatinib promoted as an innovative electrochemical sensor. After optimization of the conditions using this sensor at pH 7.0, the oxidation signal of bortezomib and dasatinib showed to be linear with drug concentrations in the range of 0.09–90 µM and 100–500 µM with a detection limit of 5.4 nM and 7.0 µM, respectively, using differential pulse voltammetry method. The values of D and electro-transfer coefficient (α) achieved 2.5 × 10⁻⁵ cm² s⁻¹ and 0.99, respectively. The proposed electrochemical sensor exhibited acceptable selectivity and sensitivity for simultaneous detection of bortezomib and dasatinib in pharmaceutical and biological samples.